Immunomodulatory properties of the vaccine adjuvant alum
- PMID: 24463269
- DOI: 10.1016/j.coi.2013.12.007
Immunomodulatory properties of the vaccine adjuvant alum
Abstract
Alum, the most common adjuvant in non-living vaccines, has a record of successful use in human vaccination where it promotes antibody-mediated protective immunity. However, alum is a poor inducer of cellular immune responses. The mechanism underlying the selective enhancement of humoral immunity is still not well understood. Here, to provide an insight into its mode of action, recent findings regarding innate immune responses induced by alum and their impact on adaptive immunity are described, with a particular emphasis on early recognition of alum, including NLRP3 and PI3 kinase activation, adjuvant-induced cell death and the release of endogenous danger signals. Expanding our knowledge of alum-induced immunomodulation will greatly enhance our capacity to rationally develop novel adjuvants with specific properties.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses.Eur J Immunol. 2012 Oct;42(10):2709-19. doi: 10.1002/eji.201242372. Epub 2012 Aug 6. Eur J Immunol. 2012. PMID: 22777876
-
The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants.Eur J Immunol. 2010 Mar;40(3):638-42. doi: 10.1002/eji.200940039. Eur J Immunol. 2010. PMID: 20201020 Review.
-
Naloxone and alum synergistically augment adjuvant activities of each other in a mouse vaccine model of Salmonella typhimurium infection.Immunobiology. 2011 Jun;216(6):744-51. doi: 10.1016/j.imbio.2010.10.005. Epub 2010 Oct 27. Immunobiology. 2011. PMID: 21093956
-
The vaccine adjuvant alum promotes IL-10 production that suppresses Th1 responses.Eur J Immunol. 2018 Apr;48(4):705-715. doi: 10.1002/eji.201747150. Epub 2018 Feb 15. Eur J Immunol. 2018. PMID: 29349774
-
Alum adjuvant: some of the tricks of the oldest adjuvant.J Med Microbiol. 2012 Jul;61(Pt 7):927-934. doi: 10.1099/jmm.0.038943-0. Epub 2011 Dec 15. J Med Microbiol. 2012. PMID: 22174375 Review.
Cited by
-
Characterization and Immunogenicity of Influenza H7N9 Vaccine Antigens Produced Using a Serum-Free Suspension MDCK Cell-Based Platform.Viruses. 2022 Aug 31;14(9):1937. doi: 10.3390/v14091937. Viruses. 2022. PMID: 36146744 Free PMC article.
-
In Vitro Pre-Clinical Evaluation of a Gonococcal Trivalent Candidate Vaccine Identified by Transcriptomics.Vaccines (Basel). 2023 Dec 13;11(12):1846. doi: 10.3390/vaccines11121846. Vaccines (Basel). 2023. PMID: 38140249 Free PMC article.
-
Modulation of immune responses using adjuvants to facilitate therapeutic vaccination.Immunol Rev. 2020 Jul;296(1):169-190. doi: 10.1111/imr.12889. Epub 2020 Jun 28. Immunol Rev. 2020. PMID: 32594569 Free PMC article. Review.
-
Systematic screening of 96 Schistosoma mansoni cell-surface and secreted antigens does not identify any strongly protective vaccine candidates in a mouse model of infection.Wellcome Open Res. 2019 Oct 16;4:159. doi: 10.12688/wellcomeopenres.15487.1. eCollection 2019. Wellcome Open Res. 2019. PMID: 31728414 Free PMC article.
-
Developments in Vaccine Adjuvants.Methods Mol Biol. 2022;2412:145-178. doi: 10.1007/978-1-0716-1892-9_8. Methods Mol Biol. 2022. PMID: 34918245 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical